The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic ...
US FDA clears Mabwell’s IND application to initiate phase IIa study of novel anti-ST2 monoclonal antibody, 9MW1911 to treat moderate-to-severe COPD: Shanghai Monday, December 29 ...
Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled ...
China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...
United News of Bangladesh (UNB) on MSN
Dhaka air second most polluted in world Monday morning
Dhaka, the densely populated capital of Bangladesh, ranked second among the world’s most polluted cities on Monday morning, ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...
Expect a high of 58 degrees that feels more like 48, with an overnight low of 33. Forecasters predict it will be very windy; ...
COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.
In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...
Detailed price information for Reviva Pharmaceuticals Hldg Inc (RVPH-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback